checkAd
    Startseite > Aktien > NKGen Biotech > Nachrichten
    NKGen Biotech Aktie
    1,4200
     
    USD
    -2,07 %
    -0,0300 USD
    Letzter Kurs 02:00:00 NYSE
    1,4000
     
    USD
    2.000 STK
    Geldkurs 10.06.24
    1,4600
     
    USD
    100 STK
    Briefkurs 10.06.24
    ISIN: US65488A1016 · WKN: A3EQS7 · SYM: NKGN · USA

    Neueste Nachrichten

    NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
    03.06.24 · globenewswire · NKGen Biotech
    NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    23.05.24 · globenewswire · NKGen Biotech
    NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
    20.05.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
    16.05.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
    29.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    25.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    24.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
    18.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
    11.04.24 · globenewswire · NKGen Biotech
    NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
    25.03.24 · globenewswire · NKGen Biotech
    NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
    04.03.24 · globenewswire · NKGen Biotech
    NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Disease
    28.12.23 · globenewswire · NKGen Biotech